ACAD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACAD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-29), ACADIA Pharmaceuticals's current share price is $17.10. ACADIA Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $3.81. ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 4.49.
The historical rank and industry rank for ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, ACADIA Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 27.83. The lowest was 3.96. And the median was 13.23.
ACAD's Cyclically Adjusted PB Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
ACADIA Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was $2.622. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.81 for the trailing ten years ended in Dec. 2023.
The historical data trend for ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 4.32 | 4.99 | 6.30 | 5.45 | 8.22 |
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 17.10 | / | 3.81 | |
= | 4.49 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, ACADIA Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:
Adj_Book | = | Book Value per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 2.622 | / | 129.4194 | * | 129.4194 | |
= | 2.622 |
Current CPI (Dec. 2023) = 129.4194.
ACADIA Pharmaceuticals Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201403 | 3.698 | 99.695 | 4.801 |
201406 | 3.526 | 100.560 | 4.538 |
201409 | 3.315 | 100.428 | 4.272 |
201412 | 3.093 | 99.070 | 4.041 |
201503 | 2.843 | 99.621 | 3.693 |
201506 | 2.545 | 100.684 | 3.271 |
201509 | 2.253 | 100.392 | 2.904 |
201512 | 1.960 | 99.792 | 2.542 |
201603 | 3.948 | 100.470 | 5.086 |
201606 | 3.596 | 101.688 | 4.577 |
201609 | 4.773 | 101.861 | 6.064 |
201612 | 4.271 | 101.863 | 5.426 |
201703 | 3.751 | 102.862 | 4.719 |
201706 | 3.393 | 103.349 | 4.249 |
201709 | 3.075 | 104.136 | 3.822 |
201712 | 2.695 | 104.011 | 3.353 |
201803 | 2.437 | 105.290 | 2.996 |
201806 | 2.118 | 106.317 | 2.578 |
201809 | 1.787 | 106.507 | 2.171 |
201812 | 3.330 | 105.998 | 4.066 |
201903 | 2.903 | 107.251 | 3.503 |
201906 | 2.692 | 108.070 | 3.224 |
201909 | 4.489 | 108.329 | 5.363 |
201912 | 4.503 | 108.420 | 5.375 |
202003 | 4.107 | 108.902 | 4.881 |
202006 | 4.213 | 108.767 | 5.013 |
202009 | 4.122 | 109.815 | 4.858 |
202012 | 3.928 | 109.897 | 4.626 |
202103 | 3.631 | 111.754 | 4.205 |
202106 | 3.517 | 114.631 | 3.971 |
202109 | 3.528 | 115.734 | 3.945 |
202112 | 3.359 | 117.630 | 3.696 |
202203 | 2.756 | 121.301 | 2.940 |
202206 | 2.687 | 125.017 | 2.782 |
202209 | 2.630 | 125.227 | 2.718 |
202212 | 2.471 | 125.222 | 2.554 |
202303 | 2.305 | 127.348 | 2.342 |
202306 | 2.423 | 128.729 | 2.436 |
202309 | 2.209 | 129.860 | 2.202 |
202312 | 2.622 | 129.419 | 2.622 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Austin D. Kim | officer: EVP & General Counsel | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Brendan Teehan | officer: EVP, COO, Head of Commercial | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Stephen Davis | director, officer: PRESIDENT AND CEO | ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
James Kihara | officer: Principal Accounting Officer | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Mark C. Schneyer | officer: Chief Financial Officer | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Laura Brege | director | C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608 |
Baker Bros. Advisors Lp | 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Douglas J Williamson | officer: Executive VP, Research & Dev | AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390 |
Srdjan R. Stankovic | officer: EVP | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Adora Ndu | director | C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120 |
Elena Ridloff | officer: EVP and CFO | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Michael J. Yang | officer: EVP AND CCO | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Elizabeth A. Garofalo | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
James M Daly | director | INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880 |
Eric Alejandro Miller | officer: Controller & PAO | C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
From GuruFocus
By Business Wire • 11-30-2023
By Business Wire • 01-19-2024
By Business Wire • 10-23-2023
By Business Wire • 12-13-2023
By Business Wire Business Wire • 06-08-2023
By Business Wire • 12-21-2023
By Business Wire • 08-02-2023
By PRNewswire • 08-16-2023
By Business Wire • 11-14-2023
By Business Wire • 11-21-2023